Commercial launch of the t:slim X2 Insulin Pump in Canada planned for 2H 2018
SAN DIEGO–(BUSINESS WIRE)-- Tandem Diabetes Care®, Inc. (NASDAQ:TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps, today announced its submission of a medical device license application to Health Canada to market its t:slim X2™ Insulin Pump with Dexcom G5® Mobile continuous glucose monitoring (CGM) integration1. The Company plans to launch the pump in Canada in the second half of 2018, subject to regulatory approvals.
“This application is another important step toward achieving our strategic goal of bringing the benefits of the t:slim X2 Insulin Pump to people outside of the United States,” said Kim Blickenstaff, President and CEO of Tandem Diabetes Care. “When available, the t:slim X2 will provide people in Canada a competitive choice in the durable insulin pump market, which we believe will be of particular interest as the only pump with Dexcom G5 Mobile CGM integration.”
The Company anticipates that the t:slim X2 Insulin Pump offered in Canada will be capable of displaying both English and French, offer a 24-hour clock, and will display glucose readings in millimoles per liter (mmol/L).
Canadian residents interested in signing up for email updates on Tandem’s plans in Canada can visit www.tandemdiabetes.com/canada